Trial Profile
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Nivolumab (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions; Therapeutic Use
- 05 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 21 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.